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The effects of vasoactive intestinal polypeptide (VIP) and of forskolin on atanine metabolism in 
hepatocytes isolated from fed and fasted rats were examined. VIP and 17,uM forskolin stimulated glucose 
production, gluconeogenesis from alanine, and ureagenesis, and inhibited glyconeogenesis to comparable 
degrees. However, combination of 17 FM forskolin with a maximal dose of VIP significantly augmented 
only the inhibition of glyconeogenesis. At lOO~M, forskolin induced metabolic responses comparable to 
those induced by glucagon, but similarly, in combination with maximal doses of VIP or glucagon, 
augmented only inhibition of glycogen synthesis. In addition to demonstrating modulation of alanine 
metabolism by VIP and forskolin, these results raise questions about the nature of the coupling between 
VIP receptor occupancy and metabolic response. 
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1. INTRODUCTION 
Vasoactive intestinal polypeptide (VIP) is an oc- 
tacosapeptide structurally related to glucagon, 
secretin, and several other biologic~ly active 
polypeptides [I]. It is thought to function mainly 
as a neurotransmitter, neuroendocrine substance, 
or neuroparacrine substance [Z], but a role as an 
enterohepatic hormone remains a distinct, if 
uncertain, possibility [3,4]. 
In isolated rat hepatocytes, VIP stimulates 
glycogenolysis [5] by activating glycogen 
phosphorylase [4,6,7] and inhibits glycogen syn- 
thesis by inhibiting glycogen synthase [4,6]. It also 
increases gluconeogenesis [5,8,9], in part by in- 
hibiting pyruvate kinase [6,7]. In hepatocytes 
isolated from fasted rats, VIP stimulates 
gluconeogenesis from 10 mM lactate or 10 mM 
dihydroxyacetone, but inhibits it from 10 mM 
pyruvate [9]. It was therefore of interest to ex- 
amine the effects of VIP on alanine metabolism, 
since this amino acid is a major gluconeogenic 
Abbreviations; DMSO, dimethyl sulfoxide; VIP, 
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substrate for liver [lo] and is transaminated to 
pyruvate as the initial step in its utilization. We 
report that in the fed rat, VIP increases 
glucon~genesis from alanine and ureagenesis, but 
not i4C02 production from [l-‘4C]alanine. In the 
fasted rat, VIP increases glucose production, 
decreases glyconeogenesis as measured by 
[ l-‘4C]galactose incorporation into glycogen, but 
has little effect on r4C02 or urea production. 
The metabolic effects of VIP in liver are general- 
ly thought to be mediated via CAMP-dependent 
mechanisms [6,7,9,11-171 (see however [l&19]). 
Although VIP binds to its receptor in hepatocytes 
with a higher affinity than glucagon binds to its 
receptor [l I], VIP elicits a much smaller rise in 
CAMP levels than does glucagon [7,9]. This is sug- 
gestive of an inability of the occupied VIP receptor 
to interact effectively with its N, regulatory protein 
in hepatocyte membranes [151. 
Forskolin is a diterpene that strongly activates 
adenylate cyclase in plasma membrane prepara- 
tions and in intact cells [20]. In rat cortical slices, 
very low concentrations of forskolin synergistically 
augment hormone activation of adenyiate cyclase 
[20). For some hormones, including VIP, this is 
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manifested as an increase in hormonal potency, for 
others, as an increase in hormonal efficacy. 
Although forskolin strongly activates the 
adenylate cyclase of hepatocyte membranes 
[21-231, the metabolic response of isolated 
hepatocytes to forskolin has not previously been 
examined. Furthermore, since forskolin appears to 
act in part by altering the interaction of occupied 
receptors with the N, regulatory protein, it was of 
interest o ascertain whether it could modify the ef- 
fects of VIP on the metabolism of alanine and 
glycogen. We report here that 17 PM forskolin by 
itself stimulates glycogenolysis, gluconeogenesis, 
and ureagenesis and inhibits glyconeogenesis, In 
the presence of high doses of VIP these effects are 
either greatly reduced or abolished, depending 
upon the metabolic response being investigated. 
2. MATERIALS AND METHODS 
2. I. Hepatocyte isolation 
Isolated hepatocytes were prepared by the 
method of [24], as modified in [4], from male 
Sprague-Dawley rats weighing between 140 and 
320 g. The rats were either fed Purina rat chow ad 
libitum or fasted for 24 h, as specified; water was 
available ad libitum. The procedure was routinely 
begun between 09:30 and 10:30. Hepatocyte 
viability, judged by trypan blue exclusion, was 
consistently greater than 85 (70. 
2.2. Hepatocyte incubation 
Hepatocytes were incubated (at 5-10 mg 
hepatocyte protein per ml) in 50 ml-capacity 
polycarbonate Erlenmeyer flasks in a total volume 
of 2.0 ml Krebs-Ringer bicarbonate buffer (pH 
7.4) containing 5 mM Hepes, 1.5 mM CaClz, 
3.4% (w/v) dialyzed bovine serum albumin, 
0.2 mg/ml bacitracin, 0.5% (v/v) DMSO, and 
substrates, hormones, and other compounds as in- 
dicated in the figure and table legends. The flasks 
were gassed with 95% 0215% CO2, capped, and 
incubated at 37°C with shaking (80 cycles/min). 
Except for assays of [ I-t4C]galactose incorpora- 
tion into glycogen, incubations were terminated at 
zero or 30 min by addition of 13% (w/v) per- 
chloric acid. If r4C02 production was to be 
measured, hyamine hydroxide was subsequently 
added to hanging center wells and CO2 collected 
during a 1 h incubation at 25°C with shaking. 
For studies of [ l-14C]galactose incorporation in- 
to glycogen, 50 ~1 D-[ 1 -r4C]galactose (0.25 ,&i, 
final concentration 2.8 PM) were added to the 
hepatocyte suspension after 15 min incubation and 
the flasks regassed and recapped. After an addi- 
tional 5 min incubation, 1.5 ml hepatocyte suspen- 
sion was pipetted into 9 ml ice-cold 83% (v/v) 
ethanol, and the resultant pellet washed and 
digested with glucoamylase as in [4]. Aliquots of 
the deproteinized glucoamylase digest were 
counted for radioactivity. 
Glucose concentration was measured in KOH- 
neutralized HC104 extracts using a commercially 
available glucose oxidase system (Worthington 
Automated Glucose Reagent), essentially as in [4]. 
Radioactivity incorporated into glucose was 
measured by the sequential column chromatog- 
raphic procedure in [25] or by the formate column 
method of [26]. Urea concentration was measured 
in KOH-neutralized HClO4 extracts using a com- 
mercially available diacetyl monoxime calorimetric 
system (Sigma Urea Nitrogen no.535). Protein was 
measured by the method of [27], with bovine 
serum albumin as the standard. Radioactivities 
were counted in a Packard Tri-Carb spectrometer 
with automatic external standard for quench 
correction. 
2.3. Materials 
Collagenase (Type II) and automated glucose 
reagent were from Worthington. D-[l-14C]Galac- 
tose was from Research Products. All other 
radiolabeled substrates and ACS scintillant were 
from Amersham. Hydrofluor scintillant was from 
National Diagnostics, hyamine hydroxide from 
New England Nuclear and forskolin from 
Calbiochem. Some of the porcine VIP used was a 
gift from Dr Viktor Mutt (Karolinska Institute, 
Stockholm). Insulin-free glucagon was a gift from 
Dr R.J. Hosley (Eli-Lilly, Indianapolis). The re- 
mainder of the VIP, the urea nitrogen reagent, 
bovine serum albumin, and all other incubation- 
mixture components were from Sigma. All other 
chemicals were of the highest grade available. 
2.4. Statistical significance 
Within individual experiments, incubations were 
performed in triplicate. Statistical significance was 
measured by paired or unpaired Student’s t-test, as 
appropriate. 
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3. RESULTS 
The traces through the open symbols in fig.1 
depict the VIP dose-response curves for glucose 
production, label incorporation from [ I-i4C]galac- 
glucose, and urea production in 
3Or 
VIP CONCENTRATION (nM) 
Fig. 1. Effects of VIP and moderate-dose forskolin on 
glucose production, [l-14C]alanine metabolism, and 
ureagenesis in hepatocytes from fed rats. Results are 
means f SE for between 5 and 7 experiments. 
Hepatocytes from fed rats were isolated and incubated 
with 4 mM alanine as described in section 2. Glucose 
production (0, l ), label incorporation into glucose 
from [1-i4C]alanine (0, n ), and urea production (A, A) 
were measured at various VIP concentrations (between 
0 and 300 nM) in the presence (a, n , A) or absence 
(0, 0, A) of 17pM forskolin. * P < 0.05 vs no 
forskolin. ** P < 0.01 vs no forskolin. 
hepatocytes isolated from fed rats and incubated in 
the presence of 4 mM alanine. Previous work has 
shown that 300 nM VIP maximally activates 
glycogenolysis and gluconeogenesis . Here, this 
dose of VIP increased glucose production by 72% 
(fig.lA). The response was not significantly af- 
fected by omission of alanine from the incubation 
medium (data not shown), suggesting that the 
glucose production predominantly reflected 
glycogenolysis. In support of this, incorporation 
of label from [l-‘4C]alanine into glucose amounted 
to only 13% of total glucose production under 
basal conditions (fig.lB). VIP (300 nM) increased 
this incorporation of label by 46%, which then ac- 
counted for 11% of total glucose production. 
Label incorporation into CO2 was about 6 times 
that into glucose, but was unaffected by VIP 
(means 4 SE of 112 f 8 and 116 f 
12 nmol/30 min per mg protein in the absence and 
presence of 300 nM VIP, respectively). The 
amount of alanine transaminated to form pyruvate 
was presumably about equal to 14C incorporation 
into CO2 plus glucose. Urea production (fig.lC) 
could account for about three-quarters of the 
nitrogen so generated under basal conditions. In 
the presence of 300 nM VIP, urea production in- 
creased by an amount comparable to the increase 
in gluconeogenesis. 
Initial experiments showed that forskolin did 
not affect [ 1-‘4C]alanine metabolism or glycogen- 
olysis if the forskolin was dissolved in ethanol 
(final concentration 28.4 mM), in accordance with 
[23]. All subsequent experiments were conducted 
with 0.5% (v/v) DMSO as carrier, as this solvent 
affects adenylate cyclase function only minimally 
[23 1. The traces through the filled symbols in fig. 1 
depict the VIP dose-response curves in the pre- 
sence of 17 pM forskolin, a dose sufficient to 
achieve near-maximal adenylate cyclase activation 
in isolated rat hepatocyte membranes [21,22]. 
Forskolin, by itself, increased glucose produc- 
tion by 72070 (fig.lA), gluconeogenesis by 44% 
(fig.lB), and urea production by 21% (fig.lC). 
The effects of forskolin and low doses of VIP were 
approximately additive. However, with increasing 
concentrations of VIP the augmentation of the 
response by 17 PM forskolin steadily decreased un- 
til, at 300 nM VIP, it was insignificant. In view of 
the fact that much larger glycogenolytic, 
gluconeogenic, and ureagenic responses could be 
409 
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induced (e.g., by glucagon, as in table 3), this lack 
of additivity was surprising. Formation of 14C02 
was also examined, but again showed no signifi- 
cant response to forskolin or to VIP plus forskolin 
(116 f 8 and 118 + 10 nmol/min per mg protein, 
respectively). 
[ l-‘4C]Alanine metabolism in hepatocytes 
Table 1 
isolated from 24-h fasted rats was also examined 
(table 1). VIP increased glucose production by 
25% but had little effect on incorporation of label 
from [l-14C]alanine into CO2 or on urea produc- 
tion. Forskolin, by itself, increased glucose pro- 
duction by 19070, but did not affect 14C02 or urea 
production. Concurrent administration of VIP 
Effects of VIP and moderate-dose forskolin on glucose production, ureagenesis, and 
r4C02 production in hepatocytes from 24-h fasted rats 
VIP Forskolin Glucose 
production 
Urea 
production 
[ 1 -14C] Alanine 
- i4c02 
- - 37.2 + 1.4 77.0 + 6.8 69.1 + 2.0 
+ - 46.3 f 2.2b 78.5 + 4.8 72.5 f l.6a 
- + 44.3 + 3.8a 76.3 f 6.9 71.1 f 2.1 
+ + 44.3 + 4.8b 80.7 + 3.8 75.1 * l.2b 
a P < 0.05 vs (- ) VIP/( -) forskolin 
b P < 0.001 vs (-) VIP/( -) forskolin 
Results are means +- SE for 3 experiments. Hepatocytes from 24-h fasted rats were 
isolated and incubated with 4 mM [1-14C]alanine as described in section 2. DMSO 
(O.SOro) r 17 gM forskolin dissolved in DMSO was present in all flasks. VIP, when 
present, was 300 nM. Results are expressed as nmol/30 min per mg protein 
Table 2 
Effects of forskolin, VIP, and glucagon on [l-14C]galactose incorporation into 
glycogen in hepatocytes from 24-h fasted rats 
Hormone Forskolin [ 14C]Glycogen 
production 
Forskolin [r4C]Glycogen 
production 
- - 
VIP - 
Glucagon - 
1.00 - 1.00 
0.51 f 0.05 - 0.76 f 0.04 
0.23 jl 0.05 - 0.38 f 0.04 
- 17 /cM 0.88 f o.02c 100 pM 0.35 f 0.03b 
VIP 17 ,uM 0.45 * OJW 100 PM 0.34 + 0.02a 
Glucagon 17fiM 0.22 * 0.02 100 FM 0.27 f 0.02b 
* P < 0.05 vs (- ) forskolin 
b P < 0.02 vs (-) forskolin 
’ P < 0.01 vs (-) forskolin 
[14C]Glycogen production is expressed relative to basal conditions. Values are 
means f SE for 4 experiments (17 PM forskolin) or means with range for two 
experiments (100 /cM forskolin). Hepatocytes from 24-h, fasted rats were isolated and 
incubated as described in section 2. Final substrate concentrations were 30 mM glucose 
and 4 mM alanine, with tracer amounts [l-‘4C]galactose. DMSO (O.SOro) r forskolin 
dissolved in DMSO was present in all flasks. Final hormone concentrations were 
300 nM VIP and 100 nM glucagon 
410 
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Table 3 
Effects of forskolin, VIP, and glucagon on glucose production, fl-‘4C]alanine labeling 
of glucose, and urea production in hepatoeytes from fed rats 
Hormone Forskolin Glucuse 
production 
f’4C]GIucQse 
production 
Urea 
production 
- - 1.00 1.00 1.00 
VIP 1.62 f 0.02 1.40 I 0.01 1.13 f 0.03 
cilucagon - 2.13 -I 0.05 1.98 ztz 0.02 1.38 f 0.08 
+ 1.86 f 0.04 1.90 +_ 0.02 1.35 rf: 0.09 
VIP + 2.05 f 0.01 2.13 f 0.10 1.37 jl: O&9 
Glucag0n + 2.08 a 0.02 1.90 + 0.02 1.28 f 0.20 
Responses are expressed relative to basal conditions. Basal rates (mean f SE) were 
X78 $. 4, 19.2 2 1,4, and 54,2 + 3.0 nmul/30 min per mg protein for total glucose, 
[‘4C]glucosel and urea production, respectively. Values are means with range for two 
experiments. flepatueytes from fed rats were incubated with 4 mM Il-‘4C]alanine as 
described in section 2. DMS0 (0.5%) or 1OOpM forskolin dissolved in DMSO was 
present in all flasks. Final hormone concentrations were 300 nM VIP and 100 nM 
glucagon 
and forskolin elicited resI~~~~es no diffe;ent from 
those elicited by VIP alone. 
D-[l-*4C]Galactose can be used to label the 
glycogen precursor pool through its conversion via 
gaXactose 1 -phosphate and UDP-galactose into 
UDP-glucose [283. It thus bypasses the glucose 
&phosphate pool, and so provides a straightfor- 
ward estimate of intracellular glycogen synthase 
activity [29]. Authors in [S] found, under a variety 
of conditions, that incorporation of radioactivity 
from 2.5 /cM [l-‘“Clgalactose was linearly and 
positively correlated (r= 0.91) with glycogen syn- 
thase 11 activity measured in vitro. In the present 
experiments, 300 nM VIP, 100 nM glucagon, and 
17 FM forskolin each significantly inhibited 
[1-14C]galactose incorporation into glycogen in 
hepatocytes from fasted rats (table 2). Forskolin 
plus VIP was only m~ginally more effective than 
VIP alone in inhibiting this i~~orporatiun; fur- 
skolin plus glucagon was no more effective than 
glucagon alone. 
In view of its efficacy in hepatocyte membrane 
preparations (i.e. J a IO-fold stimulation of 
adenylate cydase at equivalent concentrations 
(IZl-23]), it was surprising that l?$M forskolin 
was relatively ineffective in mudulating hepatocyte 
metabolism. The effects of a larger dose were 
therefore investigated (tables 2 and 3). Forskohn at 
IOO~M, by itself, was as effective as glucagon in 
eliciting metabolic responses, with the possible ex- 
ception of glucose production. In combination 
with either VIP or glucagon, this dose of forskofin 
did not elicit greater glucose production, 
[14C]glucose formation from [1-i4C]alanine, or 
urea production in the fed rat than that elicited by 
glucagon alone (table 3). In fasted rats, however, 
100 pM forskolin plus glucagon elicited a stronger 
inhibition af [1-i4C]galactose incorporation into 
glycogen than did glucagon alone (table 2). 
4. DISCUSSION 
These investigations demonstrate that in addi- 
tion to its gfycogenolytic and anti-glyconeogenic 
effects, VIP also modulates amino acid 
metaboIism, stimulating glu~oneogenesis from 
alanine (fed and fasted rats) and ureagenesis (fed 
rats). Forskolin, at moderate concentrations, can 
mimic most of these effects of VIP but, in com- 
bination with a maximal dose of VIP, does not 
significantly augment them, except for the inhibi- 
tion of glycogen synthetase in hepatocytes from 
fasted rats. At a higher concentration, forskolin 
can mimic the metabolic effects of glucagon but, 
similarly, in combination with maximal doses uf 
VIP or ghrcagon, does nut augment them, except 
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Volume i 73, number 2 FEBSLE’M’ERS August 1984 
(again) for the inhibition of glycogen synthetase. 
Glucagon stimulates glu~oueogenesis when lac- 
tate but not when pyruvate is the sole substrate 
[30]. This phenomenon has been ascribed to 
cytosolic NARH inhibition of membrane-bound 
low-& CAMP phosphodiesterase. Presumably, in 
the experiments of [9], the cytosolic NADH 
generated by the conversion of lactate or dihydrox- 
yacetone to pyruvate augmented the elevation of 
CAMP levels by VIP, and this did not occur with 
pyruvate. The conversion of alanine to pyruvate by 
tra~samination alss generates NADH, albeit in the 
mitochondria via glutamate dehydrogenase& This 
nevertheless appears sufficient to produce reducing 
substrate-like behavior with VIP. 
The relative importance of transport cellular 
metabolism in the control of the rate of alanine 
metabolism remains unsettIed, but it is clear that 
transport is responsive to hormonal and dietary 
factors and is potentially a major regulatory site 
1311. Authors in [323 have demonstrated a biphasic 
stimulation of alanine uptake by glucagon. The 
earlier phase appears to depend upon membrane 
h~erpolarization~ and be mediated by selective 
pot-assium efflux; the later phase (detectable at 
10 min) appears to require protein synthesis and be 
mediated by the rise in cAMP 1331. Whether either 
of these are involved in the stimulation by VIP of 
alanine metabolism remains to be determined. 
Coincident with the VIP stimulation of 
gluconeogenesis from alanine in the fed rat is a 
stimulation of ureagenesis. This has previously 
been noted for glucagon and may be mediated via 
increases in mitu~hondrial ATP 1341 or aspartate 
f35], or activation of mit~~hu~drial g utaminase 
136,331 I 
Previous work has documented that forskolin is 
as potent: an activator of adenylate cyclase in intact 
cells as it is in membrane preparations [20], and 
that the 17 PM concentration used here should ac- 
tivate adenylate cyclase production to about the 
same degree as maximal doses of glucagon [21]. 
Forskolin has no direct effects on cAMP 
phosphadiesterase activity [Xl], though glucagon 
(and presumably forskolin) will stimulate this en- 
zyme via a ~~P~mediated mechanism [38,39]. 
Nevertheless, the metabolic responses observed for 
17 FM forskolin averaged only abuut 60% of those 
observed for 1OOpM forskolin or IO0 nM 
glucagon, A similar discrepancy has been observed 
412 
in adipocytes, where maximal stimulation of 
lipolysis requires a greater elevation in CAMP 
levels when forskolin is used than when iso- 
proteronal is used I40]. 
The inability of 13 pM forskolin in the presence 
of 300 nM VIP to further stimulate alanine or 
glycogen metabolism in hepatocytes isolated from 
fed rats was also unexpected, especially in view of 
the ability of IQOpM forskolin to do so and the 
substanti~ metabolic response to 17 FM forskolin 
alone. One of several possible mechanisms that 
could lead to this is a competition between VIP- 
receptor complexes and forskolin molecules for N, 1 
proteins. In view of the results described in the 
preceding paragraph, though, the possibility arises 
that an additional second messenger is active in 
mediating the metabolic responses to VIP. This 
has also been suggested by authors in [ 381, who 
observed no increase in CAMP content with VIP 
stimulation of liver slices. Similarly, studies of 
VIP- or secretin-stimulation of pancreatic acinar 
cells report correlation of enzyme secretion with 
VIP-receptor occupation only, despite secretin in- 
ducing a lO-fold greater elevation of cAMP [41]. 
Clearly, much remains to be learned concerning 
the coupling between VIP-receptor occupancy and 
metabolic responses in hepatocytes. 
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